Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Fineline Cube Apr 30, 2026
Company

Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments

Fineline Cube Nov 10, 2023

Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023,...

Company Deals

AimingMed Partners with Becton, Dickinson and Co. to Advance Tumor Precision Medicine

Fineline Cube Nov 10, 2023

AimingMed, a leading provider of tumor precision medicine solutions based in Hangzhou, has announced a...

Company Drug

China’s NMPA Grants Conditional Approval for Juventas’ CAR-T Therapy Inaticabtagene Autoleucel

Fineline Cube Nov 10, 2023

The National Medical Products Administration (NMPA) has conditionally approved the marketing of inaticabtagene autoleucel (CNCT...

Policy / Regulatory

China’s NMPA Officially Seeks Membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S)

Fineline Cube Nov 10, 2023

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Eli Lilly’s Zepbound Approved by FDA for Chronic Weight Management in Adults

Fineline Cube Nov 10, 2023

Eli Lilly (NYSE: LLY) has received registration approval from the US Food and Drug Administration...

Company

BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase

Fineline Cube Nov 10, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...

Company Deals Hospital

Danaher Corporation Partners with CHEA to Boost Oncology Centers in Chinese Counties

Fineline Cube Nov 10, 2023

US-based science and technology services giant Danaher Corporation (NYSE: DHR) has entered into a partnership...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore HSA Nod for Phase I Study of 177Lu-LNC1003

Fineline Cube Nov 10, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

SanegeneBio Partners with Huadong Medicine to Develop RNAi Therapeutics for Metabolic Diseases

Fineline Cube Nov 10, 2023

Suzhou-based RNA interference (RNAi) therapeutics developer SanegeneBio has entered into a partnership with compatriot firm...

Company Drug

Chongqing Lummy Pharmaceutical’s Generic Ramosetron Passes GQCE in China

Fineline Cube Nov 10, 2023

China-based Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) has announced that its generic version of...

Company Deals

Shanghai Qingyun Pharmaceutical Teams Up with Organon at CIIE for Remeron Marketing

Fineline Cube Nov 10, 2023

China’s Shanghai Qingyun Pharmaceutical Technology Co., Ltd has entered into a partnership with US-based Organon...

Company Medical Device

Sino Medical Sciences Technology Secures EU MDR Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Nov 10, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received Medical...

Company Deals

Biosmelt Pharma Partners with Shenzhen Eureka Biotechnology for Cell and Gene Therapy Advancements

Fineline Cube Nov 10, 2023

Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with...

Company Deals

Bayer Secures Multiple Procurement Deals at the 6th CIIE

Fineline Cube Nov 10, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, Germany-headquartered Bayer (ETR: BAYN) announced...

Company Deals

ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions

Fineline Cube Nov 10, 2023

Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co.,...

Company Drug

Sirius Therapeutics Pursues First-in-Human Trial for SRSD107 in Australia

Fineline Cube Nov 10, 2023

Sino-US biotech Sirius Therapeutics has announced its pursuit of Investigational New Drug (IND) approval in...

Company Drug

ImmVira’s MVR-T3011 IV Achieves Positive Outcomes in US Phase I Clinical Study

Fineline Cube Nov 10, 2023

Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in...

Company Medical Device

Establishment Labs Receives NMPA Approval for Motiva Silicone Gel-Filled Breast Implants

Fineline Cube Nov 10, 2023

US-based medical technology company Establishment Labs Holdings Inc., (NASDAQ: ESTA) has announced that it has...

Company

AstraZeneca Reports Q3 2023 Revenue Growth and Oncology Milestones

Fineline Cube Nov 10, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released its financial results for the third...

Company Drug

Novartis’ Remibrutinib Meets Milestones in Late-Stage Chronic Spontaneous Urticaria Studies

Fineline Cube Nov 10, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that two late-stage studies for its Bruton’s...

Posts pagination

1 … 439 440 441 … 660

Recent updates

  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
  • Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
  • Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
  • Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
  • AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Company

Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.